private:altheos
|
1923648
|
Dec 3rd, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 3rd, 2020 08:49AM
|
Dec 3rd, 2020 08:49AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Dec 2nd, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 2nd, 2020 11:11AM
|
Dec 2nd, 2020 11:11AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Dec 1st, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 1st, 2020 09:47AM
|
Dec 1st, 2020 09:47AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 30th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 30th, 2020 10:06AM
|
Nov 30th, 2020 10:06AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 29th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 29th, 2020 04:52PM
|
Nov 29th, 2020 04:52PM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 28th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 28th, 2020 12:44PM
|
Nov 28th, 2020 12:44PM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 27th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 27th, 2020 09:04AM
|
Nov 27th, 2020 09:04AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 26th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 26th, 2020 10:06AM
|
Nov 26th, 2020 10:06AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 25th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 25th, 2020 12:22PM
|
Nov 25th, 2020 12:22PM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|
private:altheos
|
1923648
|
Nov 24th, 2020 12:00AM
|
Altheos
|
121
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 24th, 2020 08:56AM
|
Nov 24th, 2020 08:56AM
|
Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
|
Open
|
drug development (ocular diseases)
|
Open
|
601 Gateway Boulevard.,, Suite 250
|
South San Francisco
|
California
|
US
|
94080
|
|
Altheos
|
|
Health Care Equipment & Services
|